Eli Lilly: Pipeline, Products,Performance,Potential

Summary

Eli Lilly is a global manufacturer and distributor of pharmaceutical therapies for cancer, cardiovascular diseases, central nervous system ailments, diabetic and endocrine system disorders, and infectious diseases. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products.

Eli Lilly is a global manufacturer and distributor of pharmaceutical therapies for cancer, cardiovascular diseases, central nervous system ailments, diabetic and endocrine system disorders, and infectious diseases. Lilly's top selling product is Zyprexa, an antipsychotic for the treatment of schizophrenia, with sales in 2008 of over US$4.6 billion.

Lilly has been in operation for 120 years, in which time it has firmly established itself as a leading pharmaceutical company both domestically in the US and on a global scale. In recent times, Lilly has been consistently placed in the top ten research-based companies in terms of pharmaceutical sales and has developed a competitive product portfolio containing six blockbuster products with sales in excess of US$1 billion.

Between 2003 and 2006, Lilly made signficant introductions to this portfolio, with Byetta, Cialis, Alimta, and Cymbalta all making strong entries to their respective markets. In spite of an incrasingly difficult global pharmaceutical market, Lilly performed extremely well in fiscal 2007. All reportable segments and geographic regions recorded double-digit sales growth, whilst company income also recorded double-digit growth. Lilly's performance during this fiscal period stands out amongst many of its competitors and places the company in good stead for the short- to medium-term.

Potential to maintain Lilly's recent strong performance comes from its promising pipeline, which contains a number of novel candidate compounds and several line extensions for major products. Arzoxifene is in late-stage clinical trials and would provide a large boost to Lilly's endocrine and oncology portfolios, although enzastaurin has recently been found to be unlikely to achieve its primary endpoint of its Phase III trials, presenting a major setback. The development of Arxxant currently remains in doubt as Lilly reviews its options. LY450139 is a landmark product for Lilly, becoming the first putative disease-modifying drug for Alzheimer's disease that has reached the pipeline for a number of years.

This new strategic analysis report Eli Lilly: Pipeline Products Performance Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. Buyers of the web edition receive online access for one year via an easy-to-use interface with fast navigation and a full text search facility. All formats are the same price.

Contents

• Executive Summary
  • A Detailed and Comprehensive Overview of Current Financial Position, Company Strategy, Product and Pipeline Analysis.
• Therapeutic Area Focus
  • Key Product Analysis and Forecasting
  • Neuroscience
  • Cymbalta/Xeristar (Duloxetine)
  • Zyprexa (Olanzapine)
  • Endocrine Diseases
  • Actos (Pioglitazone)
  • Byetta (Exenatide)
  • Evista (Raloxifene)
  • Fort/Forteo/Forsteo (Teriparatide)
  • Humalog (Insulin Lispro)
  • Oncology
  • Alimta (Pemetrexed Disodium)
  • Gemzar (Gemcitabine)
  • Cardiovascular
  • Cialis (Tadalafil)
  • Effient (Prasugrel)
• Operational Data
  • A Wealth of Background and Detail
  • A Full 5-Year Financial Performance Assessment
  • Key Agreements
  • Infrastructure
  • Subsidiaries and Joint Ventures